Bod Australia has entered an agreement with New Zealand-based Manuka Honey producer, Manuka Pharma, for the development, manufacture and supply of a hemp-based, high methylglyoxal (MGS) Manuka Honey product line.
Under the HOA, Manuka Pharma will source, develop and manufacture the product, while Bod has agreed to import the finished product into Australia for packaging under Bod’s brand and logo, or any other brand or logo chosen by the Company.
Bod Australia will leverage initial sales through its established relationships with pharmacy banner groups, and independents within Australia and also target health food and supplement stores. As part of the agreement, Bod will also leverage its strategic partnerships throughout key Asian markets, most notably in China through its key daigou relationships.
Expansion into additional key markets throughout both North America and Europe will also be pursued, and the Company looks forward to updating shareholders on these expansion plans in due course.
The initial finished product will provide consumers with a source of high quality protein and essential fatty acids from the addition of hemp seeds, as well as the added health benefits of a high-grade, high MGS Manuka Honey. These benefits are well documented and include a reduction in stomach acids and acid reflux, combatting staph infections, improving sleep quality and the prevention of tooth decay and gingivitis; it may help treat acne and eczema.
While the product significantly enhances the Company’s nutritional product portfolio, a range of product line extensions are also being considered. Through the HOA, Bod Australia and Manuka Pharma will explore the ongoing opportunities around cosmetic and supplement applications to market in Australia, Asia, Europe and North America.